Using NHANES data, researchers calculated AGILE 3 + and AGILE 4 scores to determine the prevalence of advanced fibrosis and cirrhosis in patients with MASLD in the US.
Positive topline results from the phase 2 SPRING trial highlight CM-101’s anti-fibrotic, anti-inflammatory, and anti-cholestatic effects in primary sclerosing cholangitis.
The nomogram was constructed using independent risk factors for early cirrhosis and demonstrated greater diagnostic accuracy than current noninvasive fibrosis tests.
The homogenous genotyping test combines allele-specific tailed primers with SYBR-Green to facilitate fast and accurate detection of PI*S and PI*Z alleles of SERPINA1.